Auxilium On a Roll ...
Health Care: Drugs
Acorda Therapeutics Inc. (ACOR: NASDAQ)
$22.07 0.23 | 1.05%
06/04/12 - 02:48 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with ACOR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor13 Biotech Stocks Bought an...
- Contributor5 Biotech Drug-Launch Stock...
- Usergrandpicks
- UserPART 1 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 3...
- UserUndervalued Biotech's
- UserPART 1 JPMorgan 27th Annual...
- UserFerrengi Holdings
Latest ACOR Headlines from TheStreet
- FDA More Problematic Than Obamacare, Says Acorda CEO
04.24.12 | 06:04 am - BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Acorda Rises On Unusually High Volume (ACOR) 11.04.11 | 04:11 pm
- Acorda Stock Hits New 52-Week Low (ACOR) 09.29.11 | 01:09 pm
- SAC Upped Dendreon Exposure Before Blowup 08.15.11 | 05:08 pm
- 5 Biotech Drug-Launch Stocks to Watch 07.18.11 | 09:07 am
- Acorda Stock Gaps Up On Today's Open (ACOR) 05.20.11 | 09:05 am
- European Regulators Approve New Drugs 05.20.11 | 07:05 am
Press Releases for ACOR
- Robbins Umeda LLP Announces An Investigation Of Acorda Therapeutics, Inc. - Business Wire 06.04.12 | 11:06 am
- New Research Presented At 4th Collaborative Meeting Of CMSC And ACTRIMS Expands Understanding Of MS-Related Walking Impairment And Clinical Usage Of AMPYRA® - Business Wire 05.31.12 | 06:05 am
- Acorda Therapeutics Launches First-Ever Online Talk Show Focusing On Walking Problems In Multiple Sclerosis - Business Wire 05.30.12 | 07:05 am
- Acorda Therapeutics Recognized As One Of The Best Places To Work In New York State For Second Consecutive Year - Business Wire 04.30.12 | 07:04 am
- Acorda Therapeutics Presents AMPYRA® Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting - Business Wire 04.25.12 | 07:04 am
- Acorda Therapeutics Named One Of The 100 Most Trustworthy Companies By Forbes - Business Wire 04.12.12 | 07:04 am
- Acorda Therapeutics To Provide Pipeline Update At Upcoming R&D Day - Business Wire 04.10.12 | 07:04 am
- Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment With Ampyra® (Dalfampridine) Of Walking Problems In Patients With Multiple Sclerosis - Business Wire 04.02.12 | 08:04 am
- Acorda Therapeutics To Present At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 07:02 am
- Acorda Therapeutics To Present At 2012 RBC Capital Markets' Global Healthcare Conference - Business Wire 02.22.12 | 06:02 am
Partner Headlines for ACOR
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 04.17.12 | 09:04 am
- Biogen's Fampyra Launched in Canada - Analyst Blog - Zacks 04.13.12 | 06:04 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks Ripe For A Takeover - Seeking Alpha 10.28.11 | 05:10 pm
- Notable Call Options Activity in Acorda Therapeutics - Benzinga 10.13.11 | 01:10 pm
- Company News for October 6, 2011 - Corporate Summary - Zacks 10.06.11 | 10:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.12.11 | 09:07 am
